NEW YORK (GenomeWeb) – Diagnostics developer Venaxis and privately held genomics company Strand Life Sciences announced today that they are terminating their proposed merger.

The companies noted that they determined they could not complete the terms of their deal in a timely enough manner and that the uncertainty was negatively affecting their respective plans.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

360Dx reports that the US Centers for Medicare & Medicaid Services would cover next-generation sequencing-based cancer panel tests.

The Washington Post reports that a meteorologist is being considered as presidential science and technology advisor.

In PNAS this week: precision medicine strategy to screen for disease risk, genome evolution in Haemophilus influenzae, and more.

Researchers have developed a PCR-based assay to gauge whether manatees are present in waters.